Starting from March 2026, our monthly highlights will be available not only on LinkedIn but also directly on the this platform – making it easier for our global community to stay up to date with the latest in pulmonary hypertension research, clinical developments and patient resources. The other advantage is that this page can be translated in 40 languages via the embedded plug-in (orange button at bottom).
👇 Scroll down for the March highlights, organised by category.
🎤 Alliance for Pulmonary Hypertension — News & Events
- PHEPA, the Pulmonary Hypertension Expert Patient Academy, a joint project by the AfPH and PHA Europe: the video recording of the webinar announcing PHEPA is now available on the PH-KSP with a full transcript translatable in 40 languages.
- AfPH Q1 Webinar: The Future of Pulmonary Arterial Hypertension care: Where Science, AI and Telemedicine Converge: slides and video recording is available in the “Webinars” section of the PH-KSP.
🔬 Research on pulmonary arterial hypertension & chronic thromboembolic pulmonary hypertension
- Study links allergy molecule (IgE) to worsening heart function in pulmonary arterial hypertension, Pulmonary Hypertension News, March 11
- Methamphetamine-associated pulmonary arterial hypertension: a growing and distinct patient population — Journal of Heart and Lung Transplant, March 5
- Comparing survival and comorbidities between two pulmonary arterial hypertension sub-groups from the Spanish REHAP Registry, Rheumatology, February 27
- The hidden cost of pulmonary arterial hypertension: quantifying work productivity loss in working-age adults — Journal of Medical Economy, March 5
- Impact of smoking on diagnosis and survival in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, Pulmonology, 2026
- Comprehensive literature review on pulmonary arterial hypertension pathophysiology, diagnosis and management, US Cardiology Review, January 28
- Defining quality standards in congenital heart disease pulmonary arterial hypertension (PAH-CHD) and management best practices: Delphi panel consensus, Rheumatology Advances in Practice, January 2026
- Italian expert consensus on parenteral prostanoids in pulmonary arterial hypertension, Vascular Pharmacology, February 28
💊 Treatments and Clinical Trials
- Sotatercept in pulmonary arterial hypertension: a step-by-step approach, CHEST, March 4
- Treatment paradigm shifts in pulmonary arterial hypertension: evidence from a Phase 3 study in Asia on sotatercept, JACC, March 3
- United Therapeutics announces Phase 3 ADVANCE OUTCOMES results on ralenipag — March 2
- Tenax Therapeutics extends long-term study of oral levosimendan in pulmonary hypertension with preserved ejection fraction, February 2026
- Nippon Shinyaku reports progress on NS-863 trials for pulmonary arterial hypertension associated with interstitial lung disease (PH-ILD)
- Cereno Scientific receives approval for FDA-aligned Phase I study of CS014 for pulmonary hypertension associated with interstitial lung disease (PH-ILD)
🔍 Diagnosis & Risk Assessment
- Proof of concept for lung ultrasound in pulmonary hypertension diagnosis, CHEST, March 2026
- Risk stratification for pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD), ESC scientific statement, European Journal of Heart Failure, March 9
🤖 Digital Health & AI
- Assessing smartphone and wearable data to identify risk of idiopathic pulmonary arterial hypertension (IPAH), NPJ Vascular Health, March 25
📋 Guidelines & Standards of Care
- ESC launches plain language version of guidelines on cardiovascular disease in pregnancy, March 8, International Women’s Day
🤝 Patient Resources & Community
- UK PHA free resource of the month: “Driving with pulmonary hypertension”, March 2026
🌟 People & Industry News
- Martine Rothblatt, founder and CEO of United Therapeutics, included in Forbes’ America’s Greatest Innovators list
Curated by volunteers at the Alliance for Pulmonary Hypertension